The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait
© Dashti et al.; BioMed Central Ltd. 2014
Received: 10 March 2014
Accepted: 24 July 2014
Published: 28 August 2014
Escherichia coli O25b-B2-ST131 are considered virulent extra-intestinal pathogens causing serious clinical complications such as urinary tract infection and bacteraemia. Our main objectives in this study were to characterise the multi-drug resistant (MDR) isolates of this lineage in Kuwait, and to demonstrate whether reduced susceptibility is spread clonally.
A subset of 83 (10%) non-duplicate and non-selective E. coli O25b-B2-ST131 out of 832 MDR E. coli was identified and collected. Minimum inhibitory concentrations of the isolates were determined and pulsed-field gel electrophoresis was used for typing.
The majority (95.2%) of the 83 E. coli O25b-B2-ST131 harboured at least one bla gene with bla CTX-M-15 being the most prevalent. bla CTX-M-2 was present in one isolate. Also one isolate harboured bla CTX-M-56, qnr B1 and bla CMY-2 genes and carried IncF1 plasmids of about 97kb and160 kb. qnr B and qnr S were found in 8 other bla CTX-M-15 containing isolates. The bla NDM, bla IMP, bla VIM and qnr A were not detected, however, the bla OXA-48 was present in two (2.4%).
The majority of isolates harbouring qnr genes demonstrated relatedness (≥85%) by PFGE. However, the diversity in PFGE profiles for the other MDR isolates reflected the changes in population genetics of E. coli O25b-B2-ST131. We identified for the first time the appearance of bla CTX-M-2 in the Middle East and bla CTX-M-56 outside the Latin American countries. The isolate harbouring bla CTX-M-56 also contained qnr B1 and bla CMY-2 genes and carried IncF1 plasmids. The appearance of a highly virulent E. coli O25b-ST131 that is resistant to penicillins, most cephalosproins, β-lactamase inhibitors as well as fluoroquinolones is a cause for concern.
Escherichia coli belonging to the phylogenic group B2, serotype O25b:H4 and Multi-Locus Sequence Type (ST) 131 (E. coli O25b-B2-ST131), producing extended-spectrum β-lactamase (ESBL) is regarded as a major pandemic clone in community and hospitals causing serious clinical infections such as urinary tract infections and bacteraemia . It has been shown that E. coli O25b-B2-ST131 exhibits a high virulence score compared to other lineages  and is capable of acquiring antibiotic resistance by different mechanisms . The fact that E. coli O25b-B2-ST131 is able to exhibit antibiotic resistance means that the clinical environment within a hospital or community may actively select certain resistant strains  making the treatment of these infections increasingly difficult. Analysis by pulsed field gel electrophoresis (PFGE) has identified a high degree of genetic diversity among the E. coli O25b-B2-ST131 isolates; however, some types appear to be more common in certain regions than others .
An important cause of resistance in E. coli O25b-B2-ST131 is the production of β-lactamase enzymes. Some of the most prevalent of these are CTX-M-like enzymes as well as other types specifically TEM-1, TEM-24, SHV-12 and the plasmid-mediated AmpC CMY-2 . Furthermore, CTX-M-15 producing strains often co-produce both OXA-1 as well as variants of an aminoglycoside-modifying enzyme that is responsible for reduced susceptibility both to the aminoglycosides and to some fluoroquinolones expressed by aac(6)-Ib-cr genes ,. Fluoroquinolone (FQ) resistance in Enterobacteriaceae is usually caused by mutations in the chromosomal genes coding for type II topoisomerases and changes in the expression of efflux pumps and porins. The rise of plasmid-mediated FQ resistance protein Qnr  has caused concern in antimicrobial treatment of Enterobacteriaceae whereby carbapenems are considered the best therapeutic option . Nevertheless some Enterobactericeae can produce clinically important carbapenemases; the Ambler class B metallo-β-lactamases (NDM, IMP, VIM), the class A enzymes (KPC) and the class D oxacillinase enzymes (OXA-48). Until recently E. coli was less often affiliated with carbapenemases than Klebsiella pneumoniae, however, the recent emergence of bla NDM gene (New Delhi metallo-β-lactamase) on plasmids in E.coli ST131strains has caused concern . The NDM-like enzymes have been identified in different regions  including in clinical K. pneumoniae isolates from Kuwait  and Oman  in the Middle East.
The bla OXA-48 carbapenemase is mainly associated with the Tn1999-like transposon inserted into a single 62-kb IncL/M-type plasmid . It has been detected in sporadic cases; E. coli ST1196 (also containing resistance genes: bla CMY-2, bla SHV-12 and bla TEM-1) and E. coli ST1431 (containing β-lactamase genes: bla CTX-M-1, bla OXA-2 and bla TEM-1) isolated from pet dogs  and E. coli (containing bla CTX-M-15 and bla TEM-1 genes) isolated from a Belgian patient with ventilator-associated pneumonia travelling back from Egypt .
To date reports from the Middle East has been focused on the sporadic and selective E. coli O25b-B2-ST131 cases  and a comprehensive study on the epidemiology of this lineage was lacking. Therefore we aimed to address this issue by systematically characterising the multi-drug resistant (MDR) isolates of E. coli O25b-B2-ST131 recovered from patients in order to use these findings as a source for future reference studies and surveillances.
A survey of Extended Spectrum β-lactamase (ESBL)-producing Enterobacteriaceae was undertaken from January 2010 to December 2012. A subset of 832 MDR E. coli strains was collected from the microbiology laboratories of three major hospitals that serve the six governorates of Kuwait. All the three hospitals are tertiary health care providers with bed capacities of 300 for Ahmadi, 500 for Amiri and 600 for Yiaco-Adan. The average number of specimens processed each day varies from 500 to 700 which includes samples from out-patient and in-patient specialists units. 832 original isolates represent a subset of the isolates submitted to the clinical diagnostic laboratories of these centres.
Each patient was included only once in this study. A database was created based on the patients records that contained information; such as age, sex, hospital, location of care on each site, type of specimen and date of sampling. Specimens were processed by clinical staff members of the diagnostic laboratories using standard protocols. Cultures were performed on blood agar, MacConkey, Cystine lactose electrolyte deficient agar (CLED) and incubated aerobically and anaerobically as required. All isolates were identified at the species level based on colony morphology, biochemical analysis and by using Vitek2 (Vitek AMS; bioMrieux Vitek Systems Inc., Hazelwood, MO, USA). The isolates were stored in 10% skim milk and at -70C.
To confirm the phylogenic grouping of E. coli O25b-B2-ST131, PCR amplification of the pabB, trpA, chuA, yjaA genes  and DNA fragment of TSPE4.C2 were carried out as described before . The products were sequenced from both directions and analysed.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was determined by automated broth microdilution method (Vitek2) (Vitek AMS; BioMrieux Vitek Systems Inc., Durham, NC, USA) and the results were analysed according to the Clinical and Laboratory Standards Institute, CLSI (2012) guidelines . The antibiotics tested in this study were: Amikacin, amoxicillin/clavulanic acid, amp/sulbactam, ampicillin, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, cefoxitin, cefpodoxime, cephalothin, ceftriazone, ciprofloxacin, gentamicin, imipenem, meropenem, levofloxacin, nitrofurantoin, norfloxacin, tetracycline, tobramycin, trimethoprim/sulfamethoxazole, piperacillin/tazobactam, pipercillin and tigecycline.
ESBL production was confirmed by vitek2 analyzer and disk diffusion. Minimum inhibitory concentration (MICs) of quinolones, fluoro-quinolones and β-lactams including carbapenems were determined using the E-test method (CLSI 2012) . Isolates that showed resistance to at least three classes of antibiotics were considered as MDR. Isolates that were detected as resistant to cefoxitin were further investigated for the presence of an amp C β-lactamase by using multiplex PCR ,.
Double-disc synergy method
ESBLs were detected as previously described  using the disc approximation and double-disc synergy methods and confirmed with cefotaxime and ceftazidime E-test ESBL strips (AB Biodisk, Biomerieux-diagnostics, Durham, NC, USA). For the disc approximation test, clavulanate diffusion from an amoxicillinclavulanate (AMC30) disc was used to test for synergy with cefotaxime, ceftazidime, cefuroxime, cefepime and cefixime (Oxoid) as described previously . For the double-disc synergy test, a ceftazidime disc (30μg) was placed 30mm away from a disc containing amoxicillinclavulanate (60/10μg). ESBL production was considered positive when an enhanced zone of inhibition was visible between the β-lactam and β-lactamase inhibitor-containing discs. For the E-test, ESBL strips containing ceftazidime and ceftazidimeclavulanate and strips containing cefotaxime and cefotaximeclavulanate were used to determine the MIC ratio according to the manufacturers instructions (AB Biodisk, Biomerieux-diagnostics, Durham, NC, USA). Cultures were incubated aerobically at 37C for 1824h. CTX-M-15 β-lactamase enzyme displays a catalytic activity toward ceftazidime.
Modified Hodge test
The test inoculum (0.5 McFarland turbidity) was spread onto Mueller-Hinton agar plates and disks containing 30μg ceftazidime (with and without 10μg clavulanic acid) and 10μg imipenem (with and without 750μg EDTA) were placed on the surface of the media. The plates were incubated at 37C overnight. P. aeruginosa NCTC 10662, E. coli NCTC 10418, and S. aureus NCTC 6571 were used as controls on every plate.
Identification of resistance genes
The presence of resistant genes listed below was investigated by PCR assays. PCR was conducted in a GeneAmp 9700 (Perkin-Elmer, Waltham Massachusetts, USA) system using the conditions specified for each primer; corresponding to the source references. bla TEM-1& bla SHV, bla CTX-M-like, bla NDM, bla OXA-1, qnr A and qnr S , qnr B , aac(6)-Ib Ib-cr, gyr A & par C , gyr B & par E ; intI 1  & intI 2 , bla VIM , bla IMP, bla OXA-48, amp C , IS.
Amplified PCR products were purified with Qiagen purification kit (Qiagen Valencia, CA, USA) according to the manufacturers instructions and both strands were sequenced by automated AB13100 DNA sequencer (Applied Biosystems, Carlsbad, CA, USA) system. The BLAST program of the National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov) was used to search and compare databases for similar nucleotide acid sequences.
Pulsed-field gel electrophoresis
Pulsed-Field Gel Electrophoresis (PFGE) analysis was based on techniques described elsewhere . After PFGE, the gels were stained with ethidium bromide and scanned. The analysis of the gels was performed using BioNumerics software version 7.1 (Applied Maths, Ghent, Belgium). This software facilitates the development of the algorithms necessary for the comparison of profiles of isolates based on the Dice coefficient and the hierarchic unweighted pair arithmetic average algorithm. Cluster analysis and phylogenetic trees were subsequently analysed with an optimization of 1.0% and a tolerance of 0.7%. Isolates were considered to belong to the same PFGE clone if their Dice similarity index was ≥85%.
Plasmids were extracted (Promega, Fitchburg, WI, USA) and characterized by PCR as described previously . Plasmids from clinical isolates were detected using PFGE. A single block was incubated at 55C for 1hour with 1 unit of S1 nuclease (New England Biolabs, Ipswich, MA, USA) in Zinc Buffer (200μl of 50mM NaCl, 30mM sodium acetate and 5mM ZnSO4). Electrophoresis was performed at 6V, 5-50s for 20h .
Resistance transfer assays
Mating experiments were performed with E. coli J62-2(RifR) as the recipient strain. Cultures of the donor (KOC-10 harbouring bla CTX-M-56, qnr B1 and bla CMY-2 genes) and the recipient strain were grown in Luria-Berani (LB) broth (109cfu/ml) and mixed in the ratio of 1:4 and incubated for 5hours at 37C. Transconjugates (0.1ml) were selected on LB agar plates containing rifampicin (150mg/L) and cefotaxime (2mg/L). The transconjugates were tested for antibiotic resistance followed by PCR of the resistance determinants.
Bacterial isolates and the detection of O25b-ST131
The distribution of 832 isolates by hospital, year, and sample from which the isolates were originally recovered
The distribution of 83 isolates by hospital, year, and sample from which the isolates were originally recovered
PCR amplification and sequencing
Molecular characterization of bla genes among E. coli O25b-B2-ST131in Kuwait
Profiles of the antibiotic resistance genes
No. of isolates (%)
bla TEM-1, bla SHV-12
bla CTX-M-15, bla SHV-12
bla CTX-M-15, bla TEM-1
bla CTX-M-15, bla TEM-1, bla SHV-12
Class 1 integrons were identified in 30 (36.1%) isolates and only 5 (6%) contained class II integrons. None of the isolates contained both classes of integrons.
Quinolone resistance determinants
The profile of quinolone resistant E. coli O25b-B2-ST131isolates
Profiles of the antibiotic resistance genes
No. of Isolates
bla CTX-M-56, bla cmy-2, qnr B1
bla CTX-M-15, aac(6 )-Ib-cr, bla TEM-1, qnr B1
bla CTX-M-15, aac(6 )-Ib-cr, bla OXA-1, bla TEM-1, qnr B1, ISEcp 1
bla CTX-M-15, aac(6 )-Ib-cr, bla OXA-1,, bla TEM-1, qnr S1, ISEcp 1
bla CTX-M-15, aac(6 )-Ib-cr, bla OXA-1,, qnr B1, qnr S1
bla CTX-M-15, aac(6 )-Ib-cr, bla OXA-1,, qnr S1, ISEcp 1
bla CTX-M-15, qnr S1, bla OXA-1,, ISEcp 1
No mutations were detected in the quinolone-resistance-determining regions of gyr A. However, there was a new mutation in isolate D-140 topoisomerase subunit IV at position 520G to C that altered 174 Val (GTC) to Leu (CTC) possibly not leading to any additional chromosome encoded fluoroquinolone resistance. We also observed mutations in isolate Y-190 in topoisomerase subunit IV; the amino acid 560A→V and at position 840V→A.
We identified 3 (3.6%) of the E. coli O131 isolates did not contain β-lactam resistance genes which reflect the infection caused by cephalosporin-susceptible clones (KOC-3, KOC-47 and Y-136). These isolates were collected from two different hospitals, all from urine specimens and were not related by PFGE to each other but were closely related to other isolates that contained bla CTX-M-15 (Figure2).
This manuscript reports the trend of E. coli O25b-ST131 isolated non-selectively in hospitals. During our two year study 10% of MDR E. coli isolated belonged to the E. coli O25b-ST131 clonal group indicating that the Middle East has joined the countries affected by this virulent pathogen posing a major public health concern. MDR E. coli O25b-ST131isolates were isolated from different age groups of patients (3-94 years old; with the average age of 54.4years old).
The majority of isolates (38.6%) harboured only bla CTX-M-15 and 10.8% also contained bla TEM and or bla SHV. Among ESBL producers; we detected the presence of bla CTX-M-56 for the first time in the Middle East and outside the South American continent . The patient from which the isolate was recovered had an international travel history to an endemic region. Also we detected bla CTX-M-2, one of the dominant Asian β-lactamases  for the first time in the Middle East. bla CTX-M-56 gene is in the same context as bla CTX-M-2 by a single nucleotide mutation (G824A), resulting in a replacement of serine by asparagine at position 275 . Previously no explanation was given as to what this change means, however we propose that based on other class A β-lactamases ,, as this modification takes place at the C terminal of the α-11 helix it is involved in the resistance to inactivation by β-lactamase inhibitors. The isolate harbouring bla CTX-M-56 also contained qnr B1 and bla CMY-2 genes and carried IncF1 plasmids of about 97kb and160 kb. Production of plasmid AmpC such as cmy genes confers resistance to all penicillins, most cephalosporins and currently available β-lactamase inhibitors. Therefore the emergence of a clinical isolate that contains bla CMY-2 as well as bla CTX-M-56 poses a risk to combination β-lactam/ β-lactamase inhibitor therapy.
We also detected the presence of qnr genes in eight other bla CTX-M-15 harbouring isolates. Although Qnr enzyme by itself produces low-level resistance to quinolones, its presence facilitates the selection of higher-level resistance, thus contributing to the alarming increase in resistance to quinolones.
ISEcp 1-bla CTX-M-15 element was located in the upstream region of 33% of isolates harbouring bla CTX-M-15. Twenty seven per cent of which were associated with bla SHV, bla TEM as well as bla CTX-M-15. ISEcp 1 plays a role in gene transfer or in providing a promoter for β-lactamase genes and supports their dissemination . IncFII plasmid that also harboured bla OXA-1 and the aminoglycoside/fluoroquinolone acetyl transferase aac(6)-Ib-cr gene (aac(6)-Ib Ib-cr) was present in 59 (71%) of isolates of which 33 (40%) contained both genes. Two isolates containing bla OXA-48 contained ISEcp 1 and class 1 integrons. It has been reported  that a novel Tn1999 transposon inserted into a single 62-kb IncL/M-type plasmid is responsible for the dissemination of bla OXA-48 gene in E. coli strains.
The rate of carriage of MDR E. coli O25b-ST131 is estimated at 7% in healthy adults ; however the rate of E. coli O25b-ST131 susceptible to extended-spectrum cephalosporins has never been reported. We identified 3.6% of the E. coli O131 isolates did not contain any of the related resistance genes which reflect the infection caused by cephalosporin-susceptible clones.
We did not find any association between resistance profiles and genotypes. However; we detected for the first time the appearance bla CTX-M-2 in the Middle East and bla CTX-M-56 outside Latin America. We also identified the spread of qnr B1 and qnr S1 in isolates harbouring aac(6)-Ib Ib-cr and bla CTX-M. The isolate harbouring bla CTX-M-56 also contained qnr B1 and bla CMY-2 genes and carried IncF1 plasmids. In conclusion the appearance of a highly virulent E. coli O25b-ST131 that is resistant to penicillins, most cephalosproins, β-lactamase inhibitors as well as floroquinolones is a cause for concern and poses a risk to combination β-lactam/ β-lactamase inhibitor therapy.
AAD, LV, MMJ and SE all participated equally in the design of the study, processing the samples, laboratory experiments and analysing the data. LV drafted the manuscript. All authors read and approved the final manuscript.
The authors would like to thank Miss Shorooq Barrak Al-Inizi for her technical support. The authors would also like to acknowledge the Research Unit for Genomics, Proteomics and Cellomics Studies (OMICS) of the Health Sciences Centre, Kuwait University (Project No. SRUL02/13) for assisting in DNA sequencing.
This work was supported by Kuwait University Research Administration Grant number NM02/10 and the Kuwait Foundation for Advancement of Science (KFAS), Grant no. 2011130204.
- Peirano G, Pitout JDD: Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010, 35: 316-321. 10.1016/j.ijantimicag.2009.11.003.View ArticlePubMedGoogle Scholar
- Dahbi G, Mora A, Lpez C, Alonso MP, Mamani R, Marzoa J, Coira A, Garca-Garrote F, Pita JM, Velasco D, Herrera A, Viso S, Blanco JE, Blanco M, Blanco J: Emergence of new variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum β-lactamases. Int J Antimicrob Agents. 2013, 42: 347-351. 10.1016/j.ijantimicag.2013.06.017.View ArticlePubMedGoogle Scholar
- Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N: Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the United States. J Antimicrob Chemother. 2006, 58: 665-668. 10.1093/jac/dkl309.View ArticlePubMedGoogle Scholar
- Lau SH, Kaufmann MK, Livermore DM, Woodford N, Willshaw GA, Cheasty T, Stamper K, Reddy S, Cheesbrough J, Bolton FJ, Fox AJ, Upton M: UK epidemic Escherichia coli strains A E, with CTX-M-15 β-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother. 2008, 62: 1241-1244. 10.1093/jac/dkn380.View ArticlePubMedGoogle Scholar
- Pitout JDD, Gregson DB, Campbell L, Laupland KB: Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary health region from 2000 to 2007: Emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother. 2007, 2009 (53): 2846-2851.Google Scholar
- Johnson JR, Johnson B, Clabots C, Kuskowski MA, Pendyala S, DebRoy C, Nowicki B, Rice J: Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother. 2010, 54: 546-550. 10.1128/AAC.01089-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Amyes SG, Walsh FM, Bradley JS: Best in class: a good principle for antibiotic usage to limit resistance development?. J Antimicrob Chemother. 2007, 59: 825-826. 10.1093/jac/dkm059.View ArticlePubMedGoogle Scholar
- Prez-Prez FJ, Hanson ND: Detection of plasmid-mediated AmpC β-Lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002, 40: 2153-2162. 10.1128/JCM.40.6.2153-2162.2002.View ArticleGoogle Scholar
- Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, Lpez C, Corts P, Llagostera M, Leflon-Guibout V, Puentes B, Mamani R, Herrera A, Coira MA, Garca-Garrote F, Pita JM, Blanco J: Molecular epidemiology of Escherichia coli producing extended-spectrum β-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2009, 63: 1135-1141. 10.1093/jac/dkp122.View ArticlePubMedGoogle Scholar
- Mora A, Herrera A, Mamani R, Lpez C, Alonso MP, Blanco JE, Blanco M, Dahbi G, Garca-Garrote F, Pita JM, Coira A, Bernrdez MI, Blanco J: Recent emergence of clonal group O25b:K1:H4-B2-ST131 ibeA strains among Escherichia coli poultry isolates, including CTX-M-9-producing strains, and comparison with clinical human isolates. Appl Environ Microbiol. 2010, 76: 6991-6997. 10.1128/AEM.01112-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Vetting MW, Hegde SS, Fajardo JE, Fiser A, Roderick SL, Takiff HE, Blanchard JS: Pentapeptide repeat proteins. Biochemistry. 2006, 45: 1-10. 10.1021/bi052130w.PubMed CentralView ArticlePubMedGoogle Scholar
- Nordmann P, Poirel L: Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother. 2005, 56: 463-469. 10.1093/jac/dki245.View ArticlePubMedGoogle Scholar
- Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann P: Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect Dis. 2010, 10: 832-10.1016/S1473-3099(10)70279-6.View ArticlePubMedGoogle Scholar
- Woodford N, Turton JF, Livermore DM: Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011, 35: 736-755. 10.1111/j.1574-6976.2011.00268.x.View ArticlePubMedGoogle Scholar
- Nordmann P, Poirel L, Carrer A, Toleman MA, Walsh TR: How to detect NDM-1 producers. J Clin Microbiol. 2011, 49: 718-721. 10.1128/JCM.01773-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Mantengoli E, Luzzaro F, Pecile P, Cecconi D, Cavallo A, Attala L, Bartoloni A, Rossolini GM:Escherichia coli ST131 producing extended-spectrum β-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clin Infect Dis. 2011, 52: 690-691. 10.1093/cid/ciq194.View ArticlePubMedGoogle Scholar
- Jamal W, Rotimi VO, Albert MJ, Khodakhast F, Udo EE, Poirel L: Emergence of nosocomial New Delhi metallo-β-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae in patients admitted to a tertiary care hospital in Kuwait. Int J Antimicrob Agents. 2012, 39: 183-184. 10.1016/j.ijantimicag.2011.10.002.View ArticlePubMedGoogle Scholar
- Dortet L, Poirel L, Al Yaqoubi F, Nordmann P: NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman. Clin Microbiol Infect. 2012, 18: E144-E148. 10.1111/j.1469-0691.2012.03796.x.View ArticlePubMedGoogle Scholar
- Poirel L, Carbonnelle E, Bernabeu S, Gutmann L, Rotimi V, Nordmann P: Importation of OXA-48-producing Klebsiella pneumoniae from Kuwait. J Antimicrob Chemother. 2012, 67: 2051-2052. 10.1093/jac/dks167.View ArticlePubMedGoogle Scholar
- Stolle I, Prenger-Berninghoff E, Stamm I, Scheufen S, Hassdenteufel E, Guenther S, Bethe A, Pfeifer Y, Ewers C: Emergence of OXA-48 carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in dogs. J Antimicrob Chemother. 2013, 68: 2802-2808. 10.1093/jac/dkt259.View ArticlePubMedGoogle Scholar
- Grisold AJ, Hoenigle M, Ovcina I, Valentin T, Fruhwald S: Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. J Infect Chemother. 2013, 19: 1214-1217. 10.1007/s10156-013-0628-3.View ArticlePubMedGoogle Scholar
- Zowawi HM, Balkhy HH, Walsh TR, Paterson DL: β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 2013, 26: 361-380. 10.1128/CMR.00096-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Clermont O, Bonacorsi S, Bingen E: Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol. 2000, 66: 4555-4558. 10.1128/AEM.66.10.4555-4558.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Rupp E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E: Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15 producing strains. J Antimicrob Chemother. 2009, 64: 274-277. 10.1093/jac/dkp194.View ArticlePubMedGoogle Scholar
- Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21. 2012, CLSI, Wayne, PAGoogle Scholar
- Pitout JD, Gregson DB, Church DL, Laupland KB: Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis. 2007, 13: 443-448. 10.3201/eid1303.060447.PubMed CentralView ArticlePubMedGoogle Scholar
- Dashti AA, Jadaon MM, Gomaa HH, Noronha B, Udo EE: Transmission of a Klebsiella pneumoniae clone harbouring genes for CTX-M-15-like and SHV-112 enzymes in a neonatal intensive care unit of a Kuwaiti hospital. J Med Microbiol. 2010, 59: 687-692. 10.1099/jmm.0.019208-0.View ArticlePubMedGoogle Scholar
- Sonnevend A, Al Dhaheri K, Mag T, Herpay M, Kolodziejek J, Nowotny N, Usmani A, Sheikh FA, Pal T: CTX-M-15-producing multidrug-resistant enteroaggregative Escherichia coli in the United Arab Emirates. Clin Microbiol Infect. 2006, 12: 582-585. 10.1111/j.1469-0691.2006.01413.x.View ArticlePubMedGoogle Scholar
- Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P: Multiplex PCR for detection of plasmid-medicated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother. 2007, 60: 394-397. 10.1093/jac/dkm204.View ArticlePubMedGoogle Scholar
- Cattoir V, Weill FX, Poirel L, Fabre L, Soussy CJ, Nordmann P: Prevalence of qnr genes in Salmonella in France. J Antimicrob Chemother. 2007, 59: 751-5744. 10.1093/jac/dkl547.View ArticlePubMedGoogle Scholar
- Park CH, Rovicsek A, Jacoby GA, Sahm D, Hooper DC: Prevalence in the United States of aac(6)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother. 2006, 50: 3953-3955. 10.1128/AAC.00915-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Mammeri H, Van De Loo M, Poirel L, Martinez-Martinez L, Nordmann P: Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother. 2005, 49: 71-76. 10.1128/AAC.49.1.71-76.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Giraud E, Brisabois A, Martel JL, Chaslus-Dancla EP: Comparative study of mutations in animal isolates and experimental in-vitro and in-vivo mutation of Salmonella spp. suggests a counter selection of highly fluoroquinolone resistant strains in the field. Antimicrob Agents Chemother. 1999, 43: 2131-2137.PubMed CentralPubMedGoogle Scholar
- Mazel D, Dychinco B, Webb VA, Davies J: Antibiotic resistance in the ECOR collection: Integrons and identification of a novel aad gene. Antimicrob Agents Chemother. 2000, 44: 1568-1574. 10.1128/AAC.44.6.1568-1574.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Snez Y, Brias L, Domnguez E, Zarazaga M, Vila J, Torres C: Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains of human, animal, and food origins. Antimicrob Agents Chemother. 2004, 48: 3996-4001. 10.1128/AAC.48.10.3996-4001.2004.View ArticleGoogle Scholar
- Kiratisin P, Apisarnthanarak A, Saifon P, Laesripa C, Kitphati R, Mundy LM: The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum beta-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn Microbiol Infect Dis. 2007, 58: 349-355. 10.1016/j.diagmicrobio.2007.02.005.View ArticlePubMedGoogle Scholar
- Ribot FM, Fair NA, Gautom R, Carmeron DN, Hunter SB, Swaminathan B, Barrett TJ: Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157, Salmonella and Shigella for pulsenet. Foodborne Pathog Dis. 2006, 3: 59-67. 10.1089/fpd.2006.3.59.View ArticlePubMedGoogle Scholar
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ: Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005, 63: 219-228. 10.1016/j.mimet.2005.03.018.View ArticlePubMedGoogle Scholar
- Mshana SE, Imirzalioglu C, Hossain H, Hain T, Domann E, Chakraborty T: Conjugative IncFI plasmids carrying CTX-M-15 among Escherichia coli ESBL producing isolates at a University hospital in Germany. BMC Infect Dis. 2009, 9: 97-10.1186/1471-2334-9-97. doi:10.1186/1471-2334-9-97PubMed CentralView ArticlePubMedGoogle Scholar
- Khan MA, Lemmens N, Riera E, Blonk T, Goedhart J, Van Belkum A, Goessens W, Hays JP, Van Westreenen M: Dominance of CTX-M-2 and CTX-M-56 among extended-spectrum β-lactamases produced by Klebsiella pneumoniae and Escherichia coli isolated in hospitals in Paraguay. J Antimicrob Chemother. 2009, 64: 1330-1332. 10.1093/jac/dkp382.View ArticlePubMedGoogle Scholar
- Suzuki S, Shibata N, Yamane K, Wachino JI, Ito K, Arakawa Y: Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother. 2009, 63: 72-79. 10.1093/jac/dkn463.View ArticlePubMedGoogle Scholar
- Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, Gotuzzo E, Kronvall G, Paradisi F, Rossolini GM: Rapid dissemination and diversity of CTX-M Extended-Spectrum β-Lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother. 2007, 51: 2720-2725. 10.1128/AAC.00026-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Chabi EB, Sirot D, Paul G, Labia R: Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother. 1999, 43: 447-458. 10.1093/jac/43.4.447.View ArticleGoogle Scholar
- Du bois SK, Marriott MS, Amyes SG: TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. J Antimicrob Chemother. 1995, 35: 7-22. 10.1093/jac/35.1.7.View ArticlePubMedGoogle Scholar
- Poirel L, Decousser JW, Nordmann P: Insertion sequence ISEcp1B is involved in expression and mobilization of a blaCTX-M betalactamase gene. Antimicrob Agents Chemother. 2003, 47: 2938-2945. 10.1128/AAC.47.9.2938-2945.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Potron A, Nordmann P, Rondinaud E, Jaureguy F, Poirel L: A mosaic transposon encoding OXA-48 and CTX-M-15: towards pan-resistance. J Antimicrob Chemother. 2013, 68: 476-477. 10.1093/jac/dks397.View ArticlePubMedGoogle Scholar
- Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM: Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M Enzymes in Three Major Escherichia coli Lineages from the United Kingdom, All Belonging to the International O25:H4-ST131 Clone. Antimicrob Agents Chemother. 2009, 53: 4472-4482. 10.1128/AAC.00688-09.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.